Jori Fleisher

ORCID: 0000-0001-5003-9091
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Parkinson's Disease Mechanisms and Treatments
  • Dementia and Cognitive Impairment Research
  • Health Systems, Economic Evaluations, Quality of Life
  • Neurological disorders and treatments
  • Health Literacy and Information Accessibility
  • Stroke Rehabilitation and Recovery
  • Chronic Disease Management Strategies
  • Family and Disability Support Research
  • Cerebral Palsy and Movement Disorders
  • Medication Adherence and Compliance
  • Autism Spectrum Disorder Research
  • Alzheimer's disease research and treatments
  • Amyotrophic Lateral Sclerosis Research
  • Family Support in Illness
  • Botulinum Toxin and Related Neurological Disorders
  • Balance, Gait, and Falls Prevention
  • Long-Term Effects of COVID-19
  • Palliative Care and End-of-Life Issues
  • Family Caregiving in Mental Illness
  • Pharmaceutical studies and practices
  • Mental Health and Patient Involvement
  • Health Policy Implementation Science
  • Cerebrospinal fluid and hydrocephalus
  • Occupational Therapy Practice and Research
  • RNA regulation and disease

Rush University Medical Center
2018-2025

University of Illinois Chicago
2025

Rush University
2018-2024

University of Pennsylvania
2013-2024

Thomas Jefferson University
2024

University of Miami
2024

University of California, San Diego
2024

South Australian Health and Medical Research Institute
2024

New York University
2015-2020

Institute of Neurological Sciences
2020

Optimal management in expert centers for Parkinson's disease (PD) usually involves pharmacological and non-pharmacological interventions, delivered by a multidisciplinary approach. However, there is no guideline specifying how this model should be organized. Consequently, the nature of care varies widely.

10.3233/jpd-202078 article EN Journal of Parkinson s Disease 2020-05-19
Christopher S. Chen Edward Franklin Y Li Nelly Joseph‐Mathurin Anthony S. Burns and 95 more G Wang Tammie L.S. Benzinger Randall J. Bateman Richard J. Perrin Sonal Agrawal Lei Yu Lisa L. Barnes David A. Bennett Julie A. Schneider Martha Clare Morris Genevieve Stein-O’Brien Ryan G. Palaganas Elaine C. Meyer Javier Redding‐Ochoa Olga Pletnikova H Guo William R. Bell Juan C. Troncoso Richard L. Huganir Adam Seth Levine Julie Bennett Chantel Cacciotti Samantha J DeMarsh Adriana Rodrigues Fonseca Guerreiro Stuecklin Jordan R. Hansford Louise E. Ludlow M. Aaron MacNeil Jean M. Mulcahy Levy Parag G. Patil Ashley Plant Beverley Wilson Fleming Richard Graham Joseline Haizel‐Cobbina Yoshiko Nakano Salmo Raskin Christopher Dunham Craig Erker C Li Mona Nasrallah E. C. Nelson Mohit Rana M Santi-Vicini Frank van Landeghem J Vel Azquez Vega Richard Yuditskiy Michael C. Dewan Uri Tabori Cynthia Hawkins Kenneth Aldape D. Hoang Elizabeth P. Shulman Emma M. Campagnolo Zied Abdullaev H Lalchungnunga Om V. Singh Eric A. Stone Eytan Ruppin Y. Zhu Darin D. Carabenciov D Johnson Jorge Trejo‐Lopez Andrew Nguyen A Raghunathan G Lanzino Cristiane M. Ida Zepeda Mendoza Giannini Mayo Professor Nikhil Patel Lynn M. Bekris Shane Formica Debby W. Tsuang Cyrus P. Zabetian Irene Litvan Jori Fleisher Sarah Berman David J. Irwin Andrea Bozoki Carol F. Lippa F. DiFillipo Lorna M. Lopez Douglas Galasko James B. Leverenz Marvin J. Miller C.M. Ma G Dong Suresh R. Naik Gannon A. McDonough Shaokuan Mao Ann C. McKee Annie Huang Anna F. Lee Yoshiaki MATSUMOTO D Silverbush

Background: Clinical trials of anti-Aβ monoclonal antibodies in Alzheimer disease (AD) infer target engagement from Aβ positron emission tomography (PET) and/or fluid biomarkers such as cerebrospinal (CSF) Aβ42/40.However, these measure deposits indirectly incompletely.In contrast, postmortem neuropathologic assessments allow direct investigation treatment effects on brain and many other pathologic features.Methods: From a clinical trial dominantly inherited AD, we measured...

10.1093/jnen/nlae036 article EN other-oa Journal of Neuropathology & Experimental Neurology 2024-05-10

The clinical diagnosis of dementia with Lewy bodies (DLB) depends on identifying significant cognitive decline accompanied by core features parkinsonism, visual hallucinations, fluctuations, and REM sleep behavior disorder (RBD). Hyposmia is one the several supportive features. α-Synuclein seeding amplification assays (αSyn-SAAs) may enhance diagnostic accuracy detecting pathologic αSyn seeds in CSF. In this study, we examine how different associate CSF αSyn-SAA positivity a large group...

10.1212/wnl.0000000000209656 article EN Neurology 2024-07-16

Individuals with Lewy body dementia (LBD) rely on family caregivers. Caregiving demands limit caregivers’ ability to attend their own health needs, increasing vulnerability the psychological effects of caregiving. We previously piloted a peer mentoring intervention experienced (mentor) and less (mentee) LBD Matched mentor-mentee dyads spoke weekly for 16 weeks, guided by an handbook. knowledge attitudes towards improved postintervention. hypothesized that caregiver status moderates response...

10.1097/wad.0000000000000664 article EN Alzheimer Disease & Associated Disorders 2025-02-10

Parkinson's disease (PD) is a complex, multisymptom, neurodegenerative affecting primarily older adults. With progression, many individuals become homebound and removed from coordinated, expert care, resulting in excess morbidity, mortality, healthcare expenditures acute care settings institutions. Home visit models have achieved the triple aim of improving individual population health while reducing costs frail, community‐dwelling geriatric cohorts. This study details novel,...

10.1111/jgs.15337 article EN Journal of the American Geriatrics Society 2018-04-02

Objective To evaluate the effect of virtual group music therapy on apathy in people with Parkinson’s disease (PD). Introduction Apathy affects 40% PD, lacks effective therapies, and independently predicts poorer quality life greater caregiver burden. Music is clinical application to address a person’s physical or emotional needs treating dementia. Methods People idiopathic PD (Movement Disorders Society-Unified Disease Rating Scale, item ≥ 2) their caregivers participated twelve, weekly...

10.1177/08919887231176755 article EN Journal of Geriatric Psychiatry and Neurology 2023-05-18

Objectives: Many individuals with dementia Lewy bodies (DLB) die of disease-related complications, but predicting the end life can be challenging. We identified a phenotype associated approaching life. Methods: present 4 exemplar cases where DLB experienced refractory psychosis before death. reviewed codebooks and quotes from 3 studies regarding end-of-life experiences in to identify that aligned this phenotype. Results: In addition cases, family caregivers prior described prominent...

10.1097/wad.0000000000000660 article EN Alzheimer Disease & Associated Disorders 2025-01-29

Abstract Background Low health literacy ( HL ) indicates a limited ability to understand and use basic information make appropriate care decisions. Whereas low is associated with higher morbidity, mortality, costs in multiple chronic conditions, little known about its associations Parkinson's disease PD ). Methods This was cross‐sectional study of nondemented adults participating the National Parkinson Foundation Outcomes Project at University Pennsylvania. Subjects were administered two...

10.1002/mdc3.12272 article EN Movement Disorders Clinical Practice 2015-12-14

Advanced Parkinson's disease (PD) is a multidimensional neurodegenerative condition with motor and non-motor symptoms contributing to increasing disability decreasing quality of life. As the progresses, patients may become homebound estranged from neurological care, dire consequences. We describe epidemiologic burden individual risks faced by palliative-stage PD their caregivers.

10.21037/apm.2019.09.12 article EN Annals of Palliative Medicine 2019-11-18

As Parkinson disease (PD) progresses, symptoms increase, quality of life (QoL) declines, and individuals may become homebound, often losing access to neurologic care. We aimed determine whether facilitating expert in-home care could improve our understanding progression, treatment options, unmet needs in this vulnerable population, such a model mitigate decline QoL.Patients with PD meeting Medicare homebound criteria were eligible for quarterly interdisciplinary home visits over 12 months....

10.1212/cpj.0000000000000716 article EN Neurology Clinical Practice 2020-01-06

Crohn disease (CD) is primarily considered an inflammatory condition of the small and large intestine although associated extraintestinal inflammation relatively common. Ocular manifestations are generally localized to anterior chamber ocular surface but rarely can involve posterior pole, orbit, optic nerve. We report a case otherwise healthy 42-year-old man who was diagnosed with CD after presenting acute vision loss from perineuritis.

10.1097/wno.0b013e31825e8e2e article EN Journal of Neuro-Ophthalmology 2012-07-07

Acquired neuromyotonia is increasingly recognized as an autoimmune disorder, frequently associated with antibodies against voltage-gated potassium channel complex proteins.We present a case of acquired the heralding symptom recurrent thymoma in patient myasthenia gravis.A report single 53-year-old man gravis and prior thymectomy presenting 2 months diffuse, involuntary muscle twitching absence myasthenic symptoms, electrophysiologically confirmed to be neuromyotonia. Further evaluation...

10.1001/jamaneurol.2013.2863 article EN JAMA Neurology 2013-08-26

Abstract INTRODUCTION The National Institute on Aging – Alzheimer's Association (NIA‐AA) ATN research framework proposes to use biomarkers for amyloid (A), tau (T), and neurodegeneration (N) stage individuals with AD pathological features track changes longitudinally. overall aim was utilize this characterize pre‐mortem status longitudinally in a clinically diagnosed cohort of dementia Lewy bodies (DLB) correlate it the post mortem diagnosis. METHODS subtyped by cerebrospinal fluid (CSF)...

10.1002/alz.13398 article EN cc-by-nc-nd Alzheimer s & Dementia 2023-09-23

Abstract The wide application of patient engagement and its associated benefits has increased across government, academic pharmaceutical research. However, neither an identified standard practice for the process engagement, nor utilization common metrics to assess outcomes, exists. Parkinson's Foundation developed a framework within research drug development sectors. This approach was over course several years through assessing literature, acquiring feedback from researchers people with...

10.1111/hex.13064 article EN cc-by Health Expectations 2020-05-03
Coming Soon ...